MAPK8 and Alzheimer disease: Supplementation with NMN in AD transgenic mice also attenuates mitochondrial respiratory deficits, Aβ production, and synaptic loss, and partially inhibits the activation of the JNK pathway and therefore might be a therapeutic option for AD [89,90].